~ 股東年度/特別會議將於 2026 年 1 月 30 日舉行 ~
賓夕法尼亞州韋克斯福德，2026 年 1 月 6 日（環球新聞通訊）-- Coeptis Therapeutics Holdings, Inc.（納斯達克代碼：COEP）（“Coeptis” 或 “公司”），一家下一代技術和生物製藥公司，今天宣佈其在美國證券交易委員會（“SEC”）註冊的 S-4 表格（文件編號：333-288329）（經修訂的 “註冊聲明”）已被宣佈生效，該註冊聲明與之前宣佈的與 Z Squared Inc.（“ZSQ”）的合併交易（“交易”）相關。公司將開始向截至 2026 年 1 月 2 日（“記錄日期”）營業結束時的股東郵寄與股東年度/特別會議（“股東會議”）相關的最終代理聲明/招股説明書，會議定於 2026 年 1 月 30 日舉行。股東會議的通知將於 2026 年 1 月 7 日左右郵寄給截至記錄日期的股東。
雖然合併公司已提交申請在納斯達克證券市場上市，但尚未獲得批准，且無法保證該上市申請將獲得批准，或合併公司將符合適用的上市標準。如果合併公司無法在國家證券交易所獲得上市，其證券將在交易後繼續在場外市場交易。
關於 Coeptis。
COEPTIS, Inc.及其子公司 Coeptis Pharmaceuticals, Inc.、GEAR Therapeutics, Inc.、SNAP Biosciences, Inc.和 Coeptis Technologies, Inc.（統稱 “Coeptis”）是一家生物製藥和技術公司。生物製藥部門專注於開發用於癌症、自身免疫和傳染病的創新細胞治療平台。Coeptis 旨在通過其前沿的研究和開發工作推進治療範式並改善患者結果。
公司的治療組合以從 Deverra Therapeutics 獲得的資產為基礎，包括一種異體細胞免疫療法平台和 DVX201，一種臨牀階段的未修飾自然殺傷細胞治療技術。COEPTIS 還正在開發一種從匹茲堡大學獲得的通用多抗原 CAR 技術（SNAP-CAR），以及與 VyGen-Bio 和卡羅林斯卡學院的傑出醫學研究人員合作的 GEAR 細胞治療和伴隨診斷平台。
基於其核心競爭力，COEPTIS 最近成立了一個技術部門，專注於通過先進技術增強運營能力。該部門擁有從 NexGenAI Solutions Group 獲得的人工智能驅動的營銷軟件和機器人流程自動化工具，旨在優化業務流程並提高整體效率。
COEPTIS 總部位於賓夕法尼亞州韋克斯福德，致力於在 FDA 設定的監管框架內推進其使命，確保所有活動符合最高的合規和患者護理標準。有關 COEPTIS 的更多信息，請訪問 https://coeptistx.com。
關於 Z Squared： Z Squared 致力於建立一個可持續和高效的加密貨幣挖礦運營，並在可信的中型礦工中佔據一席之地，擁有 9000 台專注於狗狗幣（DOGE）、萊特幣（LTC）的 ASIC 礦機，分別對應其 200 億美元和 60 億美元的市值。我們的目標是負責任地增長，利用先進技術和戰略運營，確立自己在美國礦業行業中的重要地位。
徵求參與者 Coeptis、Z Squared Inc.及其各自的董事、高級管理人員、其他管理成員和員工可能被視為參與徵求 Coeptis 和 Z Squared 股東對擬議交易的代理。投資者和證券持有人可以在向 SEC 提交的擬議交易的代理聲明/招股説明書中獲得有關 Coeptis 和 Z Squared 的董事和高級管理人員的姓名和在交易中的利益的更詳細信息，包括註冊聲明。
無報價或徵求 本新聞稿不構成對任何證券或擬議交易的代理、同意或授權的徵求。本新聞稿也不構成出售或徵求購買任何證券的報價，亦不應在任何州或司法管轄區進行證券的銷售，除非在該等司法管轄區的證券法下注冊或資格之前，此類報價、徵求或銷售是非法的。除非通過符合 1933 年證券法（經修訂）要求的招股説明書，否則不得進行證券的發行。
關於前瞻性聲明的警示説明 本新聞稿包含根據 1995 年《私人證券訴訟改革法》定義的前瞻性聲明。前瞻性聲明包括有關計劃、目標、策略、未來事件或業績的聲明，以及潛在假設和其他非歷史事實的聲明。當我們使用諸如 “可能”、“將”、“打算”、“應該”、“相信”、“期望”、“預期”、“項目”、“估計” 或類似表達時，這些表達並不單純與歷史事項相關，而是在做出前瞻性聲明。前瞻性聲明並不保證未來的業績，並涉及可能導致實際結果與我們在前瞻性聲明中討論的預期顯著不同的風險和不確定性。這些聲明受到重大不確定性和風險的影響，包括但不限於 Coeptis 向證券交易委員會提交的報告中包含的風險。因此，投資者被警告不要對本新聞稿中的任何前瞻性聲明過度依賴。其他因素在 Coeptis 向美國證券交易委員會的備案中進行了討論，包括註冊聲明，相關文件可在 www.sec.gov 上查閲。除非法律、法規或規則要求，Coeptis 和 Z Squared 均不承擔公開修訂這些前瞻性聲明以反映本聲明日期後發生的事件或情況的義務。
聯繫方式
IR@coeptistx.com
<img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1ERXpOQ00zTXpRME56TTFJekl5TURZek16Zz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1ERXpOQ00zTXpRME56TTFJekl5TURZek16Zz0"/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGQ4NjFlNzYtNTZiNy00YzM2LTk5MDktZjUzYzk4YWUwMDk3LTEyMTc4OTEtMjAyNi0wMS0wNi1lbg==/tiny/Coeptis-Therapeutics.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGQ4NjFlNzYtNTZiNy00YzM2LTk5MDktZjUzYzk4YWUwMDk3LTEyMTc4OTEtMjAyNi0wMS0wNi1lbg==/tiny/Coeptis-Therapeutics.png"/>

COEP

Coeptis Therapeutics 宣佈，其與 Z Squared 合併的 S-4 註冊聲明已獲得美國證券交易委員會（SEC）的有效批准。正式的代理聲明將在 2026 年 1 月 30 日的年度/特別會議之前郵寄給股東。合併後的公司已申請納斯達克上市，但批准尚待確認。如果未獲批准，股票將在 OTC Markets 交易。Coeptis 專注於創新生物製藥，而 Z Squared 則從事加密貨幣挖礦。此公告不構成對證券的招攬或出售要約

~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~
<div class="lb-trans">~ 股東年度/特別會議將於 2026 年 1 月 30 日舉行 ~
</div>WEXFORD, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, , announced today that its registration statement on Form S-4 (File No. 333-288329) (as amended, the “Registration Statement”), relating to the previously announced merger transaction (the “Transaction”) with Z Squared Inc. (“ZSQ”), has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) and that it will commence mailing the definitive proxy statement/prospectus relating to the Annual/Special Meeting (the “Stockholder Meeting”) of the Company’s stockholders to be held on January 30, 2026, in connection with the Transaction. The proxy statement/prospectus is being mailed to the Company’s stockholders of record as of the close of business on January 2, 2026 (the “Record Date”). Notice of the Stockholder Meeting will be mailed on or about January 7, 2026 to stockholders of record as of the Record Date.
<div class="lb-trans">賓夕法尼亞州韋克斯福德，2026 年 1 月 6 日（環球新聞通訊）-- Coeptis Therapeutics Holdings, Inc.（納斯達克代碼：COEP）（“Coeptis” 或 “公司”），一家下一代技術和生物製藥公司，今天宣佈其在美國證券交易委員會（“SEC”）註冊的 S-4 表格（文件編號：333-288329）（經修訂的 “註冊聲明”）已被宣佈生效，該註冊聲明與之前宣佈的與 Z Squared Inc.（“ZSQ”）的合併交易（“交易”）相關。公司將開始向截至 2026 年 1 月 2 日（“記錄日期”）營業結束時的股東郵寄與股東年度/特別會議（“股東會議”）相關的最終代理聲明/招股説明書，會議定於 2026 年 1 月 30 日舉行。股東會議的通知將於 2026 年 1 月 7 日左右郵寄給截至記錄日期的股東。
</div>While the combined company has submitted an application to list the combined company’s common stock on The Nasdaq Stock Market LLC, approval has not yet been obtained and there can be no assurance that such listing application will be approved or that the combined company will meet the applicable listing standards. If the combined company is unable to obtain listing on a national securities exchange, the combined company’s securities will continue to trade on the OTC Markets following the Transaction.
<div class="lb-trans">雖然合併公司已提交申請在納斯達克證券市場上市，但尚未獲得批准，且無法保證該上市申請將獲得批准，或合併公司將符合適用的上市標準。如果合併公司無法在國家證券交易所獲得上市，其證券將在交易後繼續在場外市場交易。
</div>About Coeptis.
<div class="lb-trans">關於 Coeptis。
</div>COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies, Inc (collectively &#34;Coeptis&#34;), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
<div class="lb-trans">COEPTIS, Inc.及其子公司 Coeptis Pharmaceuticals, Inc.、GEAR Therapeutics, Inc.、SNAP Biosciences, Inc.和 Coeptis Technologies, Inc.（統稱 “Coeptis”）是一家生物製藥和技術公司。生物製藥部門專注於開發用於癌症、自身免疫和傳染病的創新細胞治療平台。Coeptis 旨在通過其前沿的研究和開發工作推進治療範式並改善患者結果。
</div>The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
<div class="lb-trans">公司的治療組合以從 Deverra Therapeutics 獲得的資產為基礎，包括一種異體細胞免疫療法平台和 DVX201，一種臨牀階段的未修飾自然殺傷細胞治療技術。COEPTIS 還正在開發一種從匹茲堡大學獲得的通用多抗原 CAR 技術（SNAP-CAR），以及與 VyGen-Bio 和卡羅林斯卡學院的傑出醫學研究人員合作的 GEAR 細胞治療和伴隨診斷平台。
</div>Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
<div class="lb-trans">基於其核心競爭力，COEPTIS 最近成立了一個技術部門，專注於通過先進技術增強運營能力。該部門擁有從 NexGenAI Solutions Group 獲得的人工智能驅動的營銷軟件和機器人流程自動化工具，旨在優化業務流程並提高整體效率。
</div>Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com.
<div class="lb-trans">COEPTIS 總部位於賓夕法尼亞州韋克斯福德，致力於在 FDA 設定的監管框架內推進其使命，確保所有活動符合最高的合規和患者護理標準。有關 COEPTIS 的更多信息，請訪問 https://coeptistx.com。
</div>About Z Squared: Z Squared is dedicated to building a sustainable and efficient cryptocurrency mining operation and is positioned among credible mid-cap miners with 9,000 actively generating ASIC miners focused on Dogecoin (DOGE), Litecoin (LTC) and addressing its $20B and $6B market caps, respectively. Our aim is to grow responsibly, leveraging advanced technology and strategic operations to establish ourselves as a significant player in the U.S. mining industry.
<div class="lb-trans">關於 Z Squared： Z Squared 致力於建立一個可持續和高效的加密貨幣挖礦運營，並在可信的中型礦工中佔據一席之地，擁有 9000 台專注於狗狗幣（DOGE）、萊特幣（LTC）的 ASIC 礦機，分別對應其 200 億美元和 60 億美元的市值。我們的目標是負責任地增長，利用先進技術和戰略運營，確立自己在美國礦業行業中的重要地位。
</div>Participants in the Solicitation Coeptis, Z Squared Inc. and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Coeptis’ and Z Squared’s stockholders with respect to the proposed Transaction. Investors and securityholders may obtain more detailed information regarding the names and interests in the Transaction of the directors and officers of each of Coeptis and Z Squared in the proxy statement/prospectus for the proposed Transaction as field with the SEC, including the Registration Statement.
<div class="lb-trans">徵求參與者 Coeptis、Z Squared Inc.及其各自的董事、高級管理人員、其他管理成員和員工可能被視為參與徵求 Coeptis 和 Z Squared 股東對擬議交易的代理。投資者和證券持有人可以在向 SEC 提交的擬議交易的代理聲明/招股説明書中獲得有關 Coeptis 和 Z Squared 的董事和高級管理人員的姓名和在交易中的利益的更詳細信息，包括註冊聲明。
</div>No Offer or Solicitation This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed Transaction. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.
<div class="lb-trans">無報價或徵求 本新聞稿不構成對任何證券或擬議交易的代理、同意或授權的徵求。本新聞稿也不構成出售或徵求購買任何證券的報價，亦不應在任何州或司法管轄區進行證券的銷售，除非在該等司法管轄區的證券法下注冊或資格之前，此類報價、徵求或銷售是非法的。除非通過符合 1933 年證券法（經修訂）要求的招股説明書，否則不得進行證券的發行。
</div>Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When we use words such as &#34;may,&#34; &#34;will,&#34; &#34;intend,&#34; &#34;should,&#34; &#34;believe,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;project,&#34; &#34;estimate&#34; or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from our expectations discussed in the forward-looking statements. These statements are subject to significant uncertainties and risks including, but not limited, to those risks contained in reports filed by Coeptis with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Coeptis’ filings with the U.S. Securities and Exchange Commission, including the Registration Statement, which are available for review at www.sec.gov. Neither Coeptis nor Z Squared undertake any obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations or rules.
<div class="lb-trans">關於前瞻性聲明的警示説明 本新聞稿包含根據 1995 年《私人證券訴訟改革法》定義的前瞻性聲明。前瞻性聲明包括有關計劃、目標、策略、未來事件或業績的聲明，以及潛在假設和其他非歷史事實的聲明。當我們使用諸如 “可能”、“將”、“打算”、“應該”、“相信”、“期望”、“預期”、“項目”、“估計” 或類似表達時，這些表達並不單純與歷史事項相關，而是在做出前瞻性聲明。前瞻性聲明並不保證未來的業績，並涉及可能導致實際結果與我們在前瞻性聲明中討論的預期顯著不同的風險和不確定性。這些聲明受到重大不確定性和風險的影響，包括但不限於 Coeptis 向證券交易委員會提交的報告中包含的風險。因此，投資者被警告不要對本新聞稿中的任何前瞻性聲明過度依賴。其他因素在 Coeptis 向美國證券交易委員會的備案中進行了討論，包括註冊聲明，相關文件可在 www.sec.gov 上查閲。除非法律、法規或規則要求，Coeptis 和 Z Squared 均不承擔公開修訂這些前瞻性聲明以反映本聲明日期後發生的事件或情況的義務。
</div>Contacts
<div class="lb-trans">聯繫方式
</div>IR@coeptistx.com
<div class="lb-trans">IR@coeptistx.com
</div><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1ERXpOQ00zTXpRME56TTFJekl5TURZek16Zz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyMDEzNCM3MzQ0NzM1IzIyMDYzMzg="/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGQ4NjFlNzYtNTZiNy00YzM2LTk5MDktZjUzYzk4YWUwMDk3LTEyMTc4OTEtMjAyNi0wMS0wNi1lbg==/tiny/Coeptis-Therapeutics.png" alt="" original-src="https://ml.globenewswire.com/media/MGQ4NjFlNzYtNTZiNy00YzM2LTk5MDktZjUzYzk4YWUwMDk3LTEyMTc4OTEtMjAyNi0wMS0wNi1lbg==/tiny/Coeptis-Therapeutics.png"/>

Coeptis Therapeutics 的 S-4 文件已被 SEC 宣佈生效，代理郵件已開始發送，預計將與 Z Squared 進行合併交易 | COEP 股票新聞